市場調査レポート
商品コード
1235287
吸入式疼痛治療薬:進化する治療薬と新たな事業機会Inhaled Pain Therapeutics: Evolving Therapeutics, Emerging Opportunities |
吸入式疼痛治療薬:進化する治療薬と新たな事業機会 |
出版日: 2023年01月31日
発行: Greystone Research Associates
ページ情報: 英文 110 Pages
納期: 即日から翌営業日
|
先進国の平均寿命が延び、人口が高齢化するにつれて、慢性および急性の疼痛の発生率と関連する罹患率が増加し、患者とその家族にとってQOLの問題である疼痛管理がより重要視されるようになってきています。
当レポートでは、吸入式疼痛治療薬の市場を調査し、疼痛管理の概要、法規制環境、需要促進因子の分析、競合情勢、参入企業のプロファイルなどをまとめています。
‘Inhaled Pain Management: Evolving Therapeutics, Emerging Opportunities’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for inhaled pain management drug therapeutics. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to inhalable formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, inhaled pain drug delivery addresses a key healthcare issue - one that is particularly problematic in aging populations and developing economies. Several of these development programs involve international partnerships designed to take advantage of perceived opportunities in regional markets.